



COHESIVE HEALTHCARE MANAGEMENT & CONSULTING

Mangum Regional Medical Center

TITLE		POLICY	
Heparin Low Dose Protocol – ACS and Stroke		DRP-007	
MANUAL	EFFECTIVE DATE	REVIEW DATE	
Drug Room	10-1-2020	10-1-2020	
DEPARTMENT	REFERENCE		
Drug Room	https://www.accessdata.fda.gov		

SCOPE

This policy applies to all adult patients receiving care and treatment at Mangum Regional Medical Center.

PURPOSE

This protocol applies to adult patients at Mangum Regional Medical Center receiving low dose heparin intravenous (IV) therapy for Acute Coronary Syndrome (ACS) or Stroke management.

PROCEDURE

Nursing Orders:

- Weigh patient STAT. Actual body weight _____ kg
- Determine Ideal Body Weight _____ kg
- Determine Adjusted Body weight _____ kg
- Determine Heparin Dosing Weight (DW): **dose using adjusted body weight if Actual Body Weight/Ideal Body Weight is greater than 1.2. DW _____ kg**

Medications:

- Heparin Sodium _____ units IV bolus STAT (_____ mL of 10,000 unit/mL vial). Bolus dose based on Heparin 60 units/kg x Dosing Weight (**Maximum of 5,000 units**)
- Heparin Sodium 25,000 units in D5W 500mL (50 units/mL) at _____ units/hour (_____ mL/hour) begin now. Heparin 12 units/kg-hour x DW (**Maximum of 1,000 units/hr initially**) _____ units/hour

Labs:

- CBC – STAT
- CMP -STAT
- PT/INR - STAT
- PTT - STAT
- PTT every 6 hours after initiation and after every Heparin rate change
- Daily weight while on Heparin Drip
- CBC every other day while on Heparin Drip
- GUAIAAC stool as needed

Monitoring Parameters:

- Draw blood for PTT from arm that doesn't have heparin infusion. Do not draw from heparin-flushed lines.
- If there is no other access other than the heparin line, then **stop** the heparin, flush the line, aspirate 10 mL of blood to waste, and then re-flush the line prior to drawing a specimen.
- Do not interrupt heparin infusion unless ordered.
- Contact medical provider if platelet count is less than 150,000 microliter or a 50% drop from baseline; hematoma, bleeding or suspected bleeding occurs.

REFERENCES

https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/017029s140lbl.pdf

ATTACHMENTS

None.

REVISIONS/UPDATES

Date	Brief Description of Revision/Change